View Item 

Show simple item record

Risk Factors for Arthralgias or Myalgias Associated with Quinupristin‐Dalfopristin Therapy
dc.contributor.authorCarver, Peggy L.en_US
dc.contributor.authorWhang, Emilyen_US
dc.contributor.authorVandenBussche, Heather L.en_US
dc.contributor.authorKauffman, Carol A.en_US
dc.contributor.authorMalani, Preeti N.en_US
dc.date.accessioned2012-03-16T15:55:10Z
dc.date.available2012-03-16T15:55:10Z
dc.date.issued2003-02en_US
dc.identifier.citationCarver, Peggy L.; Whang, Emily; VandenBussche, Heather L.; Kauffman, Carol A.; Malani, Preeti N. (2003). "Risk Factors for Arthralgias or Myalgias Associated with Quinupristin‐Dalfopristin Therapy." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 23(2). <http://hdl.handle.net/2027.42/90134>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90134
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.titleRisk Factors for Arthralgias or Myalgias Associated with Quinupristin‐Dalfopristin Therapyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumHealth System, University of Michiganen_US
dc.contributor.affiliationumCollege of Pharmacy, University of Michiganen_US
dc.contributor.affiliationumSchool of Medicine, University of Michiganen_US
dc.contributor.affiliationotherAnn Arbor Veterans Affairs Medical Center Ann Arbor, Michigan.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90134/1/phco.23.2.159.32078.pdf
dc.identifier.doi10.1592/phco.23.2.159.32078en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceLamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram‐positive infections. Drugs 1999; 58: 1061 – 97.en_US
dc.identifier.citedreferenceLivermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 2000; 46: 347 – 50.en_US
dc.identifier.citedreferenceWinston DJ, Emmanouilides C., Kroeber A., et al. Quinupristin/dalfopristin therapy for infections due to vancomycin‐resistant Enterococcus faecium. Clin Infect Dis 2000; 30: 790 – 7.en_US
dc.identifier.citedreferenceRaad I., Hachem R., Hanna H., et al. Treatment of vancomycin‐resistant enterococcal infections in the immunocompromised host: quinupristin‐dalfopristin in combination with minocycline. Antimicrob Agents Chemother 2001; 45: 3202 – 4.en_US
dc.identifier.citedreferenceMoellering RC. Quinupristin/dalfopristin: therapeutic potential for vancomycin‐resistant enterococcal infections. J Antimicrob Chemother 1999; 44 ( suppl A ): 25 – 30.en_US
dc.identifier.citedreferenceLow DE. Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Microb Drug Resist 1995; 1: 223 – 34.en_US
dc.identifier.citedreferenceOlsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin‐dalfopristin administration [online exclusive article]. Clin Infect Dis 2001; 32: e83 – 6. Available from www.journals.uchicago.eduCIDjournalcontentsv32n4.html. Accessed December 5, 2002.en_US
dc.identifier.citedreferenceLinden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycin‐resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001; 33: 1816 – 23.en_US
dc.identifier.citedreferenceJohnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 1999; 66: 492 – 500.en_US
dc.identifier.citedreferenceDrew RH, Perfect JR, Srinath L., Kirkimilis E., Dowzicky M., Talbot GH, for the Synercid Emergency‐Use Study Group. Treatment of methicillin‐resistant Staphylococcus aureus infections with quinupristin/dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2000; 46: 775 – 84.en_US
dc.identifier.citedreferenceMoellering RC, Linden PK, Reinhardt J., Blumberg EA, Bompart F., Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin‐resistant Enterococcus faecium: Synercid emergency‐use study group. J Antimicrob Chemother 1999; 44: 251 – 61.en_US
dc.identifier.citedreferenceNichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram‐positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin, or vancomycin: Synercid skin and skin structure infection group. J Antimicrob Chemother 1999: 44: 263 – 73.en_US
dc.identifier.citedreferenceRubinstein E., Prokocimer P., Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999; 44 ( suppl A ): 37 – 46.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.23.2.159.32078.pdf
Size:
33.46KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.